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OBJECTIVE: DisQ-24 is a 14-item questionnaire with a
6-point Likert-type scale that measures disability in the
24 hours following onset of headache pain. Previous
analysis on data from transformed migraine sufferers 
suggested item iterations may improve psychometric
properties. The objective of this study was to evaluate 
the Disq-24 using classical test theory (CTT) and item
response theory (IRT) methods to provide recommenda-
tion on further revisions. 
METHODS: Disq-24 data from 647 subjects who par-
ticipated in two clinical trials of acute migraine treatment
were analyzed. An exploratory factor analysis (EFA)
using maximum likelihood estimation and oblique rota-
tion was performed to determine factor structure. Based
on results from EFA, CTT and Likert scaling assumptions
of equal means, variances and weights, internal consis-
tency and item discriminant validity were examined using
the Multi-trait/Multi-item analysis software (MAP-R).
Item-characteristic curves, item discrimination (‘a’) and
difﬁculty parameters (‘b’) based on the Samejima’s graded
IRT model were estimated using Multilog software.
RESULTS: EFA suggested a 2-factor structure but com-
munality estimates for Item 8 (0.41) and Item 10 (0.46)
suggested a high proportion of variance in these items is
unexplained in the common factors. MAP-R analysis
showed most items met CTT assumptions, except items
8 and 10 had lower means (0.87 and 1.17 respectively)
and weights (1.7 and 1.8 respectively) as compared to
other items within the same subscale. All items exhibited
high item-scale correlations (0.61–0.89) and high internal
consistency (>0.9), which may suggest item redundancy.
IRT analysis showed most items provided high discrimi-
natory power (range 1.8–2.9) in differentiating varying
levels of disability and measured disability over a broad
range with no ﬂoor/ceiling effects, except items 8 
(a = 1.09) and 10 (a = 1.10) had low discrimination and
contributed little to the test information function.
CONCLUSIONS: CTT and IRT methods provided
similar results that two items may be deleted or revised
to improve psychometric properties. Further development
may consider deleting items with low discriminatory
power to reduce redundancy. Additional analysis is
needed to conﬁrm improvement of data ﬁt after revisions.
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OBJECTIVES: Approximately 120 million Americans
suffer from migraines, leading to impaired functional
capacity and substantial societal costs. Studies have
shown that migraine sufferers use more healthcare
resources than non-migraine sufferers. This study 
compares healthcare resource use among migraineurs
receiving various drug treatments. 
METHODS: Fee-for-service patients with a migraine or
headache diagnosis were selected from the MEDSTAT
MarketScan databases. Enrollment, medical claims, 
and prescriptions were analyzed from January 1, 1998
through June 30, 2000. Demographics, utilization, 
and evidence of seven comorbidities were calculated over
a baseline period of 12 months before migraine diagno-
sis. Costs for patients taking triptan monotherapy during
the 12 months after diagnosis were compared to those for
patients taking other drug therapies (butalbitals, ergota-
mines, methysergide, midrin, oral narcotics, and stadol)
over the same follow-up period. Ordinary least squares
regressions of log healthcare expenditures controlled for
demographics, utilization, and comorbidities at baseline.
Smearing estimates were used to predict the marginal
effect of drug treatment on annual healthcare 
expenditures.
RESULTS: The ﬁnal sample included 929 patients taking
triptan monotherapy and 3588 patients taking other drug
therapies. Triptan patients were more likely to be female
than other patients (83.2% vs. 73.5%, P < .001) and less
likely to have at least one comorbidity (51% vs. 56%, 
P = .006) or to visit an emergency room (25% vs. 61%,
P < .001); they also had fewer outpatient visits (5.2 vs.
7.5, P < .001). Triptan patients had higher predicted costs
from migraine-related visits and prescriptions ($4035.88
vs. $450.20, P < .0001), but lower predicted total expen-
ditures ($7468.69 vs. $8974.03, P < .0001), even after
controlling for patient differences.
CONCLUSIONS: Triptan monotherapy was associated
with lower total healthcare expenditures than were other
migraine drug therapies, even though migraine-related
costs for triptan patients were higher. The difference was
over and above the cost inﬂuence of health status as 
measured by comorbidities and prior utilization.
